Results 101 to 110 of about 50,442 (246)

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

The Squalene Oil‐in‐Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR‐Induced B‐Cell Responses

open access: yesCytometry Part A, EarlyView.
ABSTRACT For vaccination, the mechanisms of action of antigens and of immunostimulatory pathogen‐associated molecular pattern (PAMP) adjuvants are better understood than the roles of the depot, carrier, and other formulation‐related influences. Here, we carried out cytometric studies of vaccine formulations and the effect of adjuvant formulations on B ...
Egest J. Pone   +3 more
wiley   +1 more source

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?

open access: yesLupus Science & Medicine
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immune dysregulation and potentially providing long-term ...
Maria Theresa Kuipers   +1 more
openaire   +3 more sources

Immunophenotypic characteristics of plasma cells in POEMS syndrome

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract To analyze the immunophenotypic characteristics of plasma cells in patients with polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome. This retrospective study included patients with POEMS syndrome hospitalized in the Department of Hematology, Huashan Hospital, from September 2017 to August 2025 ...
Zhenhua Wang   +6 more
wiley   +1 more source

Minor population of NK lymphocytes with CD19 coexpression

open access: yesМедицинская иммунология
Single reports were published concerning a minor subpopulation of NK cells with weak coexpression of the B cell antigen CD19 in the patients’ blood and bone marrow.
A. A. Kalashnikova, N. V. Bychkova
doaj   +1 more source

Autologous Extracellular Matrix‐Based Cell‐Free Therapy for Tissue Regeneration Through Trem2+ Macrophages Mediated Angiogenesis

open access: yesExploration, EarlyView.
ADF is prepared as a cell‐free bio‐membrane from autologous adipose ECM using simple physical techniques inspired by “papermaking”. It boasts superior properties and facilitates tissue regeneration through Trem2+ macrophages‐mediated angiogenesis. ADF can be stored long‐term for personalized medicine, offering insights into autologous ECM preservation ...
Mengmeng Hou   +8 more
wiley   +1 more source

Guideline for the In Vivo Immunomodulatory Activity Test of Polysaccharide Based on Cyclophosphamide‐Induced Mouse Model

open access: yesFood Safety and Health, EarlyView.
Abstract graph of the in vivo immunomodulatory activity of polysaccharide based on a cyclophosphamide‐induced mouse model. ABSTRACT The immune system serves as the primary defense mechanism against pathogens and plays a vital role in maintaining host homeostasis. In recent years, natural polysaccharides have emerged as promising immunomodulators due to
Wenlei Nie   +3 more
wiley   +1 more source

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers

open access: yesOncoImmunology
Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an ...
Miriam Velasco-Sidro   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy